scispace - formally typeset
Y

Yunching Chen

Researcher at National Tsing Hua University

Publications -  59
Citations -  5139

Yunching Chen is an academic researcher from National Tsing Hua University. The author has contributed to research in topics: Sorafenib & Small interfering RNA. The author has an hindex of 27, co-authored 50 publications receiving 4144 citations. Previous affiliations of Yunching Chen include Academia Sinica & Harvard University.

Papers
More filters
Journal ArticleDOI

In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

TL;DR: This review discusses the key challenges to the development of the carriers for miRNA-based therapy and explores current strategies to systemically deliver miRNAs to cancer without induction of toxicity.
Journal ArticleDOI

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

TL;DR: A LPH (liposome-polycation-hyaluronic acid) nanoparticle formulation modified with tumor-targeting single-chain antibody fragment (scFv) for systemic delivery of small interfering RNA (siRNA) and microRNA (miRNA) into experimental lung metastasis of murine B16F10 melanoma significantly reduced the tumor load in the lung.
Journal ArticleDOI

Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors.

TL;DR: It is demonstrated that arsenic trioxide-induced sumoylation of PML correlates with a change of endogenous Daxx partitioning from GR-regulated gene promoter to PODs and a relief of DAXx repression on GR target gene expression, which provides mechanistic insights into DaxX in SUMO-dependent transcriptional control and subnuclear compartmentalization.
Journal ArticleDOI

Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery.

TL;DR: The new formulation of lipid coated calcium phosphate nanoparticle (NP) improved the in vitro silencing effect 3-4 folds compared to the previous LPD formulation, but had a negligible immunotoxicity.
Journal ArticleDOI

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

TL;DR: The authors showed that increased hypoxia after sorafenib treatment promotes immunosuppression, characterized by increased intratumoral expression of the immune checkpoint inhibitor programmed death-ligand 1 (PD-L1) and accumulation of Tregulatory cells and M2-type macrophages.